Advancement of infectious disease research and vaccine development has never been more important due to the massive increase in drug resistant micro-organisms. The rapid spread of infectious diseases now made possible by the unprecedented mobility of society is very concerning. Furthermore, the re-emergence of infections such as tuberculosis and emergence of new threats including Ebola, Zika, SARS and H1N1 has created fresh challenges for the clinical research fraternity and O4 is very enthused at having the opportunity to continue contributing to this area.
The O4 Research team has significant experience in conducting studies in anti-infectives, viral infections, Hepatitis B, Hepatitis C, Respiratory Syncytial Virus and HIV. We have also successfully planned and delivered high quality, cost effective & timely multi-centre vaccine studies for a variety of stakeholders, including but not limited to, multiple paediatric and adult Influenza (seasonal and pandemic) studies, dTpa-IPV/MMR, Meningococcal B, Group B streptococcus, Hib, Herpes Simplex, Herpes Zoster and HPV.